撰文丨王聪 编辑丨王多鱼 排版丨水成文 2022 年初，宾夕法尼亚大学的研究人员在 Science 期刊发表了一篇重磅研究论文 【1】 ，开发了一种 在体内原位生成 CAR-T 细胞的新技术 （ in vivo CAR- T） ，通过 注射脂质纳米颗粒 （LNP） 递送 mRNA，在体内重编程 T 细胞，使其识别心脏纤维化细胞，从而治疗心脏纤维化疾病。该方法类似于 mRNA 疫 苗，仅需简单注射，就能在体内生成 CAR-T 细胞疗法，有望解决当前 CAR-T 细胞疗法工艺复杂、周期长、价格高昂等关键难题。 不久后，该团队创立了一家名为 Capstan Therapeutics 的公司， 致力于将 in vivo CAR-T 技术应用于癌症、自身免疫疾病及纤维化疾病的治疗，该公司目前以 获得来自多家制药巨头及风投机构的 3.4 亿美元融资。该公司的 创始团队包括 Carl June （CAR-T 细胞治疗先驱） ， Drew Weissman （诺奖得主、mRNA 技 术奠基人） ， Jonathan Epstein （ in vivo CAR-T 技术发明人） 。 2025 年 6 月 11 日， Capst ...

Company Overview - Legend Biotech Corporation is a global leader in cell therapy with over 2,500 employees, making it the largest standalone cell therapy company [3] - The company is pioneering treatments that aim to revolutionize cancer care, particularly through its CAR-T cell therapy [3] - CARVYKTI, a one-time treatment for relapsed or refractory multiple myeloma, is developed and marketed in collaboration with Johnson & Johnson [3] Upcoming Events - Legend Biotech will host a conference call for investors on May 13, 2025, at 8:00 am ET to review first-quarter 2025 results [1] - Senior leaders will provide an overview of the company's performance during the call [1] - A replay of the webcast and earnings news release will be available approximately two hours after the call concludes [2]

Core Viewpoint - Mustang Bio, Inc. has exited its lease for a manufacturing facility in Worcester, Massachusetts, and divested certain fixed assets to AbbVie for $1.0 million, while relocating its corporate headquarters to Waltham, Massachusetts [1][2]. Group 1: Financial Implications - The termination of the lease is expected to result in approximately $2.0 million in cash expense savings over the next 24 months [2]. - The divestment of fixed assets to AbbVie Bioresearch Center Inc. was completed for a total of $1.0 million [1]. Group 2: Strategic Focus - The company remains committed to advancing its existing portfolio and plans to initiate a novel clinical trial with MB-109, targeting recurrent glioblastoma and high-grade astrocytomas in the second half of 2025 [3]. - MB-109 is a combination therapy that includes MB-101 (IL13Rα2-targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), aimed at enhancing the efficacy of CAR-T cell therapy by modifying the tumor microenvironment [4]. Group 3: Company Overview - Mustang Bio is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers, partnering with leading medical institutions to advance CAR-T therapies [5].